M. Levi
Schering-Plough
32 Papers
608 Citations
M. Levi is an academic researcher from Schering-Plough. The author has contributed to research in topics: Fibrinolysis & Plasminogen activator. The author has an hindex of 18, co-authored 32 publications. Previous affiliations of M. Levi include University of Amsterdam.
Chat about Author
Papers
Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.
M.C. Minnema,Philip W. Friederich,M. Levi,P. A. K. Von Dem Borne,Laurent O. Mosnier,Joost C. M. Meijers,B. J. Biemond,C. E. Hack,Bonno N. Bouma,H. ten Cate +9 more
TL;DR: In this paper, the effect of in vivo inhibition of factor XI and TAFI in an experimental thrombosis model in rabbits was investigated and it was shown that anti-factor XI antibodies in jugular vein thrombi resulted in an almost twofold increase in endogenous thrombolysis compared with a control antibody.
Systemic inflammation as a risk factor for atherothrombosis
TL;DR: Several chronic inflammatory disorders, such as systemic lupus erythematosus and rheumatoid arthritis, and chronic infections that are associated with a chronic inflammatory state, including human immunodeficiency virus (HIV) infection, areassociated with an increased incidence of cardiovascular disease (CVD).
Short-term and long-term mortality in very elderly patients admitted to an intensive care unit
TL;DR: Mortality in very elderly patients after unplanned surgical or medical ICU admission is higher than after planned admission, and the most important factors independently associated with ICU mortality were related to the severity of illness at admission.
152
Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay.
TL;DR: It is concluded that the increase in plasminogen activator activity upon the infusion of DDAVP results in the in vivo generation of plAsmin, in the absence of coagulation activation.
99
Impaired Haemostasis by Intravenous Administration of a Gelatin-based Plasma Expander in Human Subjects
TL;DR: The results demonstrated that the administration of a gelatin-based plasma substitute results in a significant impairment of primary haemostasis and thrombin generation.
98